Aromatase inhibitors: the next generation of therapeutics for endometriosis?
Authors:
- Serdar E. BulunSBSerdar E. Bulun
- 1 May 2006
- journal article
- review article
- Published by Elsevier in Fertility and Sterility
- Vol. 85 (5) , 1307-1318
Abstract
No abstract availableKeywords
This publication has 66 references indexed in Scilit:
- An overview of the pharmacology and pharmacokinetics of the newer generation aromatase inhibitors anastrozole, letrozole, and exemestaneCancer, 2002
- Aromatase inhibition improves ovarian response to follicle-stimulating hormone in poor respondersFertility and Sterility, 2002
- The Treatment of EndometriosisAnnals of the New York Academy of Sciences, 2002
- Surgical management of endometriosisBest Practice & Research Clinical Obstetrics & Gynaecology, 2000
- Estrogen production in endometriosis and use of aromatase inhibitors to treat endometriosis.Endocrine-Related Cancer, 1999
- ExemestaneDrugs, 1999
- Treatment of advanced breast cancer in postmenopausal women with 4-hydroxyandrostenedioneCancer Chemotherapy and Pharmacology, 1990
- R 76713, a new specific non-steroidal aromatase inhibitorThe Journal of Steroid Biochemistry and Molecular Biology, 1989
- Aminoglutethimide in the treatment of premenopausal patients with metastatic breast cancerEuropean Journal of Cancer and Clinical Oncology, 1986
- Suppression of estrogens with Aminoglutethimide and hydrocortisone (medical adrenalectomy) as treatment of advanced breast carcinoma: A reviewBreast Cancer Research and Treatment, 1981